SCHEMBL6984312

SCHEMBL6984312

COc1ccccc1-n1cccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
MAPK1 P28482 1/20 0.51
DRD2 P14416 4/20 0.47
DRD3 P35462 4/20 0.47
DRD4 P21917 2/20 0.47
MAPT P10636 4/20 0.44
MEN1 O00255 4/20 0.44
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 3/20 0.44
MGLL Q99685 1/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
GAA P10253 2/20 0.44
G6PD P11413 1/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
NPBWR1 P48145 1/20 0.43
HPGD P15428 1/20 0.43
CA12 O43570 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172547 0.84 NPC1 (0.47) NPC1MAPK1DRD2DRD3DRD4
SCHEMBL29186553 0.83 KDM4E (0.47) NPC1MAPK1DRD2DRD3DRD4
SCHEMBL8145577 0.82 NTRK1 (0.49) MAPK1DRD2DRD3DRD4MAPT
SCHEMBL14542966 0.81 MAPK1 (0.51) NPC1MAPK1DRD2DRD3DRD4
SCHEMBL20897188 0.81 ALDH1A1 (0.49) NPC1MAPK1DRD2DRD3DRD4
SCHEMBL14951066 0.80 KMT2A (0.55) DRD2DRD3DRD4MAPTMEN1
SCHEMBL7033553 0.80 HCRTR1 (0.45) NPC1MAPK1DRD2DRD3DRD4
SCHEMBL4341886 0.80 MAPK1 (0.67) NPC1MAPK1DRD2DRD3DRD4
SCHEMBL31589183 0.79 KDM4E (0.42) NPC1MAPK1DRD2DRD3DRD4
SCHEMBL9048500 0.79 NPC1 (0.43) NPC1MAPK1DRD2DRD3DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534437-B2 Photoredox-catalyzed direct C—H functionalization of arenes THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2026-01-27 US disclosed
US-20250059204-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2025-02-20 US disclosed
CN-113226321-B Pyrazolyl compounds and methods of use thereof 阿利安制药有限责任公司 2024-12-17 CN disclosed
EP-4448109-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS Aurigene Oncology Limited (IN) 2024-10-23 EP disclosed
WO-2023114710-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-06-22 WO disclosed
US-20230167067-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES UNIV NORTH CAROLINA CHAPEL HILL (US) 2023-06-01 US disclosed
US-20230167067-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES UNIV NORTH CAROLINA CHAPEL HILL (US) 2023-06-01 US disclosed
US-20230167067-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES UNIV NORTH CAROLINA CHAPEL HILL (US) 2023-06-01 US disclosed
US-11584720-B2 Photoredox-catalyzed direct C-H functionalization of arenes THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2023-02-21 US disclosed
US-11584720-B2 Photoredox-catalyzed direct C-H functionalization of arenes THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2023-02-21 US disclosed
US-20150209301-A1 PATCH FOR ANTI-DERMATOPHYTOSIS NICHIBAN COMPANY LIMITED (JP) 2015-07-30 US disclosed
EP-2889031-A1 ANTITRICHOPHYTOSIS SOLUTION FOR EXTERNAL USE Meiji Seika Pharma Co., Ltd. (JP) 2015-07-01 EP disclosed
EP-2881114-A1 ANTI-TRICHOPHYTIC ADHESIVE PATCH Meiji Seika Pharma Co., Ltd. (JP) 2015-06-10 EP disclosed
CN-104661661-A External liquid preparation for resisting trichophytosis MEIJI SEIKA PHARMA CO LTD 2015-05-27 CN disclosed
WO-2014164767-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. (US) 2014-10-09 WO disclosed
WO-2014164749-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. (US) 2014-10-09 WO disclosed
US-20140030209-A1 TOPICAL LIQUID AGENT FOR THE TREATMENT OF DERMATOPHYTOSIS MEIJI SEIKA PHARMA CO., LTD. (JP) 2014-01-30 US disclosed
EP-1313733-A1 PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-05-28 EP disclosed
WO-2002018382-A1 PYRAZOLOPYRIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-07 WO disclosed
US-3979141-A Pressure-sensitive recording system comprising 3'-amino-6' or 7'-(pyrazol-1-yl)fluoran compounds as color precursors MOORE BUSINESS FORMS, INC. (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584720-B2 Photoredox-catalyzed direct C-H functionalization of arenes PPOX, AOC2, AOC3 NPC1 1847/4885MAPK1 3425/4885DRD2 165/4885
US-12534437-B2 Photoredox-catalyzed direct C—H functionalization of arenes PF4, PPOX, AOC2 NPC1 2056/4885MAPK1 3813/4885DRD2 131/4885
US-20250059204-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS KAT6A, KAT2A, KAT6B NPC1 567/4885MAPK1 1559/4885DRD2 4692/4885
US-20140030209-A1 TOPICAL LIQUID AGENT FOR THE TREATMENT OF DERMATOPHYTOSIS POLR1C, CUTA, C1R NPC1 330/4885MAPK1 2683/4885DRD2 863/4885
US-20150209301-A1 PATCH FOR ANTI-DERMATOPHYTOSIS CUTA, NACA, POLR1C NPC1 1806/4885MAPK1 1099/4885DRD2 624/4885
US-20230167067-A1 PHOTOREDOX-CATALYZED DIRECT C-H FUNCTIONALIZATION OF ARENES PPOX, AOC2, AOC3 NPC1 1847/4885MAPK1 3425/4885DRD2 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.